No Data
Express News | There are five companies that have been selected for the national procurement of pipobranospiril, two of which can submit a Quote again.
Beijing Aosaikang Pharmaceutical (002755): The period of transformation pains is over, and the innovative pipeline is gradually gaining momentum.
Event: In the first three quarters of 2024, the company achieved revenue of 1.384 billion yuan, a year-on-year increase of 23.64%; net income attributable to the parent company was 0.127 billion yuan, a year-on-year increase of 168.79%. Among them, Q3 of 2024 had a revenue of 4.
Beijing Aosaikang Pharmaceutical (002755): Profit increased compared to the previous period, early molecules have BIC potential.
Event description: On October 31, 2024, beijing aosaikang pharmaceutical released the 2024 third quarter report: For the first three quarters of 2024, revenue reached 1.38 billion yuan, a year-on-year increase of 23.6%; the profit attributable to shareholders of the listed company was
Osecon: Report for the third quarter of 2024
Beijing Aosaikang Pharmaceutical (002755.SZ) net income in the third quarter increased by 296.25% year-on-year.
Galaxy10 reported on October 30th that Beijing Aosaikang Pharmaceutical (002755.SZ) released its third-quarter report. The company achieved revenue of 1.384 billion yuan in the first three quarters, a year-on-year increase of 23.64%; net income of 0.127 billion yuan, a year-on-year increase of 168.79%. In the third quarter alone, revenue reached 0.462 billion yuan, a year-on-year increase of 13.23%; net income was 51.4232 million yuan, a year-on-year increase of 296.25%.
Express News | Beijing Aosaikang Pharmaceutical: Subsidiary Nalatrexone Malate Tablets Obtained Pharmaceutical Registration Certificate
No Data
